Novel intranasal vaccine targeting SARS-CoV-2 receptor binding domain to mucosal microfold cells and adjuvanted with TLR3 agonist Riboxxim™ elicits strong antibody and T-cell responses in mice

SARS-CoV-2 continues to circulate in the human population necessitating regular booster immunization for its long-term control. Ideally, vaccines should ideally not only protect against symptomatic disease, but also prevent transmission via asymptomatic shedding and cover existing and future variant...

Descripción completa

Detalles Bibliográficos
Autores principales: Horvath, Dennis, Temperton, Nigel, Mayora-Neto, Martin, Da Costa, Kelly, Cantoni, Diego, Horlacher, Reinhold, Günther, Armin, Brosig, Alexander, Morath, Jenny, Jakobs, Barbara, Groettrup, Marcus, Hoschuetzky, Heinz, Rohayem, Jacques, ter Meulen, Jan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10029786/
https://www.ncbi.nlm.nih.gov/pubmed/36944687
http://dx.doi.org/10.1038/s41598-023-31198-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10029786/
https://www.ncbi.nlm.nih.gov/pubmed/36944687
http://dx.doi.org/10.1038/s41598-023-31198-3

Ejemplares similares